FDC Limited (NSE:FDC)
371.00
+8.60 (2.37%)
May 22, 2026, 3:30 PM IST
FDC Limited Revenue
FDC Limited had revenue of 4.65B INR in the quarter ending December 31, 2025, with 0.13% growth. This brings the company's revenue in the last twelve months to 20.78B, down -0.01% year-over-year. In the fiscal year ending March 31, 2025, FDC Limited had annual revenue of 21.08B with 8.50% growth.
Revenue (ttm)
20.78B
Revenue Growth
-0.01%
P/S Ratio
2.93
Revenue / Employee
3.03M
Employees
6,857
Market Cap
60.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | 13.33B | -109.88M | -0.82% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alembic Pharmaceuticals | 73.45B |
| Strides Pharma Science | 50.09B |
| Akums Drugs and Pharmaceuticals | 43.59B |
| Alivus Life Sciences | 25.52B |
| Sun Pharma Advanced Research Company | 18.90B |
| Aarti Pharmalabs | 18.01B |
| Innova Captab | 16.37B |
| Solara Active Pharma Sciences | 13.75B |
FDC Limited News
- 6 days ago - FDC Limited receives US FDA ANDA approval for Cefixime Oral Suspension — opens new revenue line in US antibiotic market - Business Upturn
- 2 months ago - FDC reconstitutes board committees and appoints Mohan Chandavarkar as chairman - Business Upturn
- 8 months ago - FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP - Business Upturn
- 1 year ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 1 year ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 1 year ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn